Intestinal tight junction protein expression and adipocyte sizes were lower in CKD-FMT mice than in control-FMT mice. Furthermore, CKD-FMT mice showed systemic microinflammation, increased concentrations of serum uremic solutes, fecal bacterial fermentation products and elevated lipid content in skeletal muscle. The differences in gut microbiota between CKD and control mice were mostly consistent between CKD-FMT and control-FMT mice. Conclusions Uremic dysbiosis induces IR and sarcopenia, leaky gut and lipodystrophy.Background Studies describing the activity of imipenem/relebactam against gram-negative bacilli (GNB) isolated from pediatric patients are lacking in the peer-reviewed literature. We address this deficiency by reporting on GNB tested against imipenem/relebactam as part of the Study for Monitoring Antimicrobial Resistance Trends global surveillance program. Methods In 2015-2017, 221 laboratories in 59 countries collected 9149 consecutive, aerobic or facultative GNB from pediatric patients (age less then 18 years) and 100 785 from adult patients with intraabdominal, respiratory, and urinary tract infections. Susceptibility was determined using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methodology and CLSI breakpoints (and US Food and Drug Administration breakpoints for imipenem/relebactam). Results The 4 most common species of GNB isolated from pediatric patients were Escherichia coli (40.4%), Pseudomonas aeruginosa (17.1%), Klebsiella pneumoniae (13.9%), and Enterobacter cloacae (4.7%); non-Morganellaceae Enterobacterales (NME) accounted for 70.1% of isolates. Imipenem/relebactam inhibited 97.8% of NME from pediatric patients; susceptibility to imipenem was 1.9% lower, and susceptibility to β-lactam comparators (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) was 9.2-25.2% lower. Imipenem/relebactam inhibited 94.2% of P. aeruginosa from pediatric patients; susceptibility to imipenem was 16.2% lower, and susceptibility to β-lactam comparators was 10.2-15.6% lower. Susceptibility was generally slightly higher for isolates from pediatric than adult patients. All K. pneumoniae carbapenemase (KPC)-positive isolates, 93.3% of multidrug-resistant (MDR) NME isolates, and 70.5% of MDR P. aeruginosa isolates from pediatric patients were susceptible to imipenem/relebactam. Conclusions Imipenem/relebactam provides a new treatment option for infections caused by resistant gram-negative bacilli, including KPC-positive NME, MDR NME, and MDR P. aeruginosa.Study question Does polycystic ovary syndrome (PCOS) confer an independent risk for the development of gestational diabetes mellitus (GDM), gestational hypertension (GHTN) and preeclampsia (PEC) based on analysis of the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database. Summary answer After controlling for all potential confounding effects, women with PCOS are at a 2-fold higher risk of developing GDM, a 50% increased risk for the development of GHTN and a 30% increased risk of developing PEC than women without PCOS. What is known already Currently, there is evidence of an increased prevalence of maternal pregnancy complications in women with PCOS. However, there remain significant gaps in understanding how PCOS affects the development of GDM, GHTN and PEC. This is most likely due to the complex, multifactorial etiology of PCOS, its range of potential confounders for pregnancy complications and the variable methodology of studies that have been conducted. To date, the larngs Pregnant women with PCOS are at increased risk of adverse complications in pregnancy even when they do not present with other coexisting metabolic conditions. Furthermore, it is important to also consider the risk of all other coexisting metabolic conditions frequently encountered in PCOS women, as these risks are additive and place women with PCOS at significantly increased risk for adverse complications in pregnancy. Study funding/competing interest(s) None.Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of the brain, optic nerves and spinal cord. Among persons with MS, 30% experience significant mobility impairment that requires use of a wheelchair for mobility. Exercise is an evidence-based second-line therapy that can improve mobility; however, little research has focused on individuals that use wheelchairs for mobility. Framed by social cognitive theory (SCT), we conducted a formative qualitative study examining exercise status and perceptions among 20 persons with MS who use wheelchairs for mobility. Using deductive, semantic thematic analysis, we coded for SCT variables (i.e. self-efficacy, knowledge, outcome expectations, barriers and facilitators) and identified participants as regular or inconsistent exercisers. In total, 12 participants were classified as regular exercisers and 8 inconsistent exercisers. Regular exercisers more frequently reported high self-efficacy, consistent exercise knowledge and numerous facilitators. https://www.selleckchem.com/products/jsh-23.html All participants reported some positive outcome expectations and several barriers and facilitators. These findings can inform future intervention studies supporting exercise behavior change through SCT. Strategies such as increasing self-efficacy, imparting instructional materials, shaping realistic outcome expectations and providing tools directed toward overcoming barriers and identifying facilitators may work to support the exercise endeavor of persons with MS who use wheelchairs for mobility.Background The drug-related death of a child has been linked to higher prevalence of complicated grief and mental health problems than bereavement by other causes of death. Whether this leads to an increased risk of mortality following the loss has not yet been examined. Methods Employing register data covering the years 1986-2015 and encompassing the entire Norwegian population, parents with at least one child aged 15 or older were analyzed using Cox regression. Drug-death bereaved parents were compared with both non-bereaved parents and parents bereaved by other causes of death. Results Parents bereaved by a drug-related death generally had a higher natural cause mortality throughout the follow-up. Drug-death bereaved parents had a particularly high external cause mortality in the first 2 years subsequent to bereavement when compared with non-bereaved parents (mothers hazard ratio 4.82, 95% CI = 3.11-7.47; fathers hazard ratio 2.50, 95% CI = 1.57-3.97). There was also an elevated, but significantly lower mortality risk from external causes 2 to 10 years subsequent to bereavement.